AI Article Synopsis
- Vitiligo is a skin condition that can occur as an immune response during treatment for melanoma with immune checkpoint inhibitors, like nivolumab.
- Patients with vitiligo often show a better therapeutic response to melanoma treatments, but it's unclear if this applies to amelanotic melanoma, which has little pigmentation.
- A case study of a patient with amelanotic melanoma of the esophagus treated with nivolumab showed a positive tumor response and subsequent development of vitiligo, suggesting a potential link between vitiligo and treatment effectiveness in this specific subtype.
Article Abstract
Vitiligo, an acquired depigmenting disorder of the skin that reacts against normal melanocytes, sometimes occurs as an immune-related adverse event in the treatment of melanoma with immune checkpoint inhibitors. It has been known that the occurrence of vitiligo is associated with a favorable therapeutic response in patients with melanoma, but it is not yet clear whether the association also applies to amelanotic melanoma, a minor subtype of melanoma with little or no melanin pigmentation. We report a patient with amelanotic melanoma of the esophagus who responded well to nivolumab treatment. Shortly after the tumor response, vitiligo was found on the patient's forearms. This case suggests that the occurrence of vitiligo is associated with a favorable response to nivolumab treatment for amelanotic melanoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787012 | PMC |
| http://dx.doi.org/10.1007/s13691-021-00515-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A rare and challenging case of amelanotic subungual melanoma from Syria.
Melanoma Manag
December 2024
Department of Plastic Surgery, Faculty of Medicine, University of Aleppo, Aleppo, Syria.
Subungual melanoma accounts for 1.9% of cutaneous melanomas. Amelanotic cases, comprising 15-25%, poses a significant diagnostic challenge because it can be misdiagnosed as other traumatic, inflammatory, or neoplastic conditions.
View Article and Find Full Text PDFSMARCB1-deficient malignant melanocytic uveal tumours: a new neural crest-derived tumour entity with SMARCB1-related germline predisposition.
J Pathol
January 2025
SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, Université Paris Cité, Paris, France.
Rhabdoid tumours (RT) are an aggressive malignancy affecting <2-year-old infants, characterised by biallelic loss-of-function alterations in SWI/SNF-related BAF chromatin remodelling complex subunit B1 (SMARCB1) in nearly all cases. Germline SMARCB1 alterations are found in ~30% of patients and define the RT Predisposition Syndrome type 1 (RTPS1). Uveal melanoma (UVM), the most common primary intraocular cancer in adults, does not harbour SMARCB1 alterations.
View Article and Find Full Text PDFDiagnostic and Prognostic Challenges of Oral Melanoma in Dogs: A Literature Review and 2 Case Studies.
J Vet Dent
January 2025
Specialty Oral Pathology for Animals, Geneseo, IL, USA.
Oral melanoma is the most common maxillofacial malignancy in dogs. A unique characteristic of melanoma is its ability to mimic other oral tumors, which makes it one of the most challenging oral tumors to diagnose, especially since 30% to 40% of cases are amelanotic. This article presents 2 case reports of dogs with amelanotic oral melanoma that were both diagnostically challenging.
View Article and Find Full Text PDFClinical and Multimodal Imaging Study to Differentiate Amelanotic Choroidal Lesions.
Ocul Oncol Pathol
December 2024
Anant Bajaj Retina Institute, L V Prasad Eye Institute, Hyderabad, India.
Introduction: The aim of this study was to differentiate amelanotic choroidal lesions - amelanotic choroidal melanoma, choroidal metastasis, and choroidal granuloma using multimodal imaging.
Methods: Retrospective comparative chart review was done. Patients diagnosed with the abovementioned choroidal lesions from 2015 to 2022 were included.
An Interesting Rare Case Report of Primary Amelanotic Melanoma With Distant Metastasis.
Cureus
October 2024
General Surgery, SRM Medical College Hospital and Research Centre, Chennai, IND.
Anorectal malignant melanoma (ARMM) is a rare and highly aggressive type of melanoma that originates in the anorectal area. It represents a small fraction of all melanoma cases and is often associated with poor prognosis due to its late presentation and challenging treatment options. Rectal malignant melanoma typically presents with symptoms such as rectal bleeding, pain, and obstructive symptoms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!